Published: 26 May 2021
Author(s): Stefano Barco, Frederikus A Klok
Issue: July 2021
Section: Editorial

The duration of anticoagulant treatment after a first venous thromboembolism (VTE) depends on the risk of a VTE recurrence, which is mostly determined by the presence, type, persistence, and severity of VTE provoking factors [1,2]. In particular, if a major provoking factor persists over time, i.e. as it is often the case for cancer and cancer treatment, an indefinite anticoagulant treatment is usually considered in the absence of active bleeding or severe bleeding risk factors. Vice versa, if the VTE provoking risk factor is transient, for instance a major surgical intervention or trauma, anticoagulation can be discontinued after a standard short 3-month course of anticoagulation, as the risk of recurrence is deemed to be minimal.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.